Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.43 -1.2%	$3.34	$2.71 ▼ $4.73	$664.60M	1.23	965,340 shs	1.02 million shs
AMRN Amarin	$12.54 -5.9%	$11.20	$7.08 ▼ $16.37	$276.02M	0.71	75,523 shs	128,974 shs
NRIX Nurix Therapeutics	$11.49 -1.1%	$10.85	$8.18 ▼ $29.56	$885.86M	2.15	858,046 shs	1.48 million shs
PGEN Precigen	$1.45 -2.7%	$1.43	$0.65 ▼ $2.17	$439.82M	1.84	1.37 million shs	2.11 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	-1.15%	-2.83%	+8.20%	+4.57%	+13.95%
AMRN Amarin	-5.93%	-5.36%	+14.21%	+37.17%	-14.12%
NRIX Nurix Therapeutics	-1.12%	-3.69%	+17.48%	-11.55%	-37.69%
PGEN Precigen	-2.68%	-4.61%	+9.85%	-19.89%	-7.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.2864 of 5 stars	3.5	0.0	0.0	3.2	2.5	0.6
AMRN Amarin	0.4186 of 5 stars	0.5	4.0	0.0	2.0	0.0	0.6
NRIX Nurix Therapeutics	1.0498 of 5 stars	3.4	1.0	0.0	0.6	0.8	0.0
PGEN Precigen	3.9674 of 5 stars	3.5	1.0	4.7	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	60.35% Upside
AMRN Amarin	1.00	Sell	$7.00	-44.18% Downside
NRIX Nurix Therapeutics	2.83	Moderate Buy	$30.18	162.63% Upside
PGEN Precigen	3.00	Buy	$6.00	313.79% Upside

Current Analyst Ratings Breakdown

Latest ABUS, AMRN, PGEN, and NRIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/29/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/17/2025	AMRN Amarin	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sell ➝ Sell	$20.00 ➝ $7.00
4/9/2025	NRIX Nurix Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $25.00
4/9/2025	NRIX Nurix Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $35.00
4/9/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
4/2/2025	NRIX Nurix Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
3/28/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	106.47	N/A	N/A	$0.51 per share	6.73
AMRN Amarin	$228.61M	1.14	N/A	N/A	$23.62 per share	0.53
NRIX Nurix Therapeutics	$54.55M	16.06	N/A	N/A	$7.44 per share	1.54
PGEN Precigen	$3.92M	109.19	N/A	N/A	$0.13 per share	11.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.41	N/A	N/A	N/A	-1,196.64%	-75.51%	-55.81%	8/7/2025 (Estimated)
AMRN Amarin	-$82.18M	-$3.64	N/A	N/A	N/A	-41.07%	-17.21%	-12.16%	7/30/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	N/A	-369.40%	-47.49%	-36.10%	7/10/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)

Latest ABUS, AMRN, PGEN, and NRIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.73	N/A	N/A	N/A	$16.26 million	N/A
5/14/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	-$0.13	-$0.04	-$0.13	$2.54 million	$1.76 million
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/7/2025	Q1 2025	AMRN Amarin	-$0.06	-$0.04	+$0.02	-$0.04	$50.75 million	N/A
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
AMRN Amarin	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	0.04	6.01	6.01
AMRN Amarin	N/A	3.53	2.55
NRIX Nurix Therapeutics	N/A	6.26	6.26
PGEN Precigen	N/A	3.53	3.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
AMRN Amarin	22.25%
NRIX Nurix Therapeutics	N/A
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
AMRN Amarin	3.30%
NRIX Nurix Therapeutics	7.40%
PGEN Precigen	47.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.53 million	152.65 million	Optionable
AMRN Amarin	360	20.71 million	20.02 million	Optionable
NRIX Nurix Therapeutics	300	76.24 million	70.60 million	Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable

ABUS, AMRN, PGEN, and NRIX Headlines

Recent News About These Companies

JMP Securities Reaffirms Market Outperform Rating for Precigen (NASDAQ:PGEN)

June 14, 2025 | americanbankingnews.com

Cantor Fitzgerald Weighs in on Precigen FY2026 Earnings

June 13, 2025 | americanbankingnews.com

Precigen (NASDAQ:PGEN) Earns Market Outperform Rating from JMP Securities

June 12, 2025 | marketbeat.com

Precigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutions

June 12, 2025 | finance.yahoo.com

Cantor Fitzgerald Estimates Precigen FY2026 Earnings

June 11, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Sells 792,731 Shares of Precigen, Inc. (NASDAQ:PGEN)

May 27, 2025 | marketbeat.com

Precigen (NASDAQ:PGEN) Downgraded to "Sell" Rating by Wall Street Zen

May 26, 2025 | marketbeat.com

FY2025 EPS Estimates for Precigen Cut by Cantor Fitzgerald

May 21, 2025 | marketbeat.com

HC Wainwright Decreases Earnings Estimates for Precigen

May 21, 2025 | marketbeat.com

J.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)

May 20, 2025 | theglobeandmail.com

Precigen, Inc.: Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 18, 2025 | finanznachrichten.de

Cantor Fitzgerald maintains Overweight on Precigen stock

May 17, 2025 | uk.investing.com

Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025 | prnewswire.com

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

April 16, 2025 | prnewswire.com

Is Precigen (PGEN) The Hot Biotech Stock Under $5?

March 27, 2025 | msn.com

Precigen options imply 20.1% move in share price post-earnings

March 20, 2025 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Edwards Lifesciences (EW)

March 20, 2025 | markets.businessinsider.com

4PGEN : Expert Outlook: Precigen Through The Eyes Of 4 Analysts

March 20, 2025 | benzinga.com

Precigen, Inc.: Precigen Reports Full Year 2024 Financial Results and Business Updates

March 20, 2025 | finanznachrichten.de

Precigen Reports Progress and Financial Results for 2024

March 19, 2025 | tipranks.com

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

March 19, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS, AMRN, PGEN, and NRIX Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.43 -0.04 (-1.15%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.46 +0.03 (+1.02%)

As of 06/20/2025 05:55 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Amarin NASDAQ:AMRN

$12.54 -0.79 (-5.93%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$12.75 +0.21 (+1.67%)

As of 06/20/2025 07:11 PM Eastern

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Nurix Therapeutics NASDAQ:NRIX

$11.49 -0.13 (-1.12%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$11.49 0.00 (0.00%)

As of 06/20/2025 05:10 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Precigen NASDAQ:PGEN

$1.45 -0.04 (-2.68%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.45 0.00 (0.00%)

As of 06/20/2025 06:48 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time